company background image
APLT

Applied TherapeuticsNasdaqGM:APLT Stock Report

Market Cap

US$434.3m

7D

-1.7%

1Y

-24.8%

Updated

19 Oct, 2021

Data

Company Financials +
APLT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

APLT Overview

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications.

Price History & Performance

Summary of all time highs, changes and price drops for Applied Therapeutics
Historical stock prices
Current Share PriceUS$16.59
52 Week HighUS$13.04
52 Week LowUS$29.80
Beta1.05
1 Month Change16.34%
3 Month Change-18.80%
1 Year Change-24.83%
3 Year Changen/a
5 Year Changen/a
Change since IPO76.49%

Recent News & Updates

Aug 13
Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

APLTUS BiotechsUS Market
7D-1.7%0.5%3.2%
1Y-24.8%13.6%30.0%

Return vs Industry: APLT underperformed the US Biotechs industry which returned 13.6% over the past year.

Return vs Market: APLT underperformed the US Market which returned 30% over the past year.

Price Volatility

Is APLT's price volatile compared to industry and market?
APLT volatility
APLT Beta1.05
Industry Beta0.98
Market Beta1

Stable Share Price: APLT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: APLT's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201626Shoshana Shendelmanhttps://www.appliedtherapeutics.com

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy.

Applied Therapeutics Fundamentals Summary


Earnings & Revenue

Key profitability statistics from the latest earnings report
APLT income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$103.54m
Earnings-US$103.54m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-3.96
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio2.8%

How did APLT perform over the long term?

See historical performance and comparison

Valuation

Is Applied Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: APLT ($16.59) is trading below our estimate of fair value ($79.51)

Significantly Below Fair Value: APLT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: APLT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: APLT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate APLT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: APLT is overvalued based on its PB Ratio (3.9x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Applied Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

38.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: APLT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: APLT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: APLT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: APLT's revenue (73.6% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: APLT's revenue (73.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: APLT is forecast to be unprofitable in 3 years.


Past Performance

How has Applied Therapeutics performed over the past 5 years?

-61.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: APLT is currently unprofitable.

Growing Profit Margin: APLT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: APLT is unprofitable, and losses have increased over the past 5 years at a rate of 61.1% per year.

Accelerating Growth: Unable to compare APLT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: APLT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: APLT has a negative Return on Equity (-92.08%), as it is currently unprofitable.


Financial Health

How is Applied Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: APLT's short term assets ($135.3M) exceed its short term liabilities ($23.4M).

Long Term Liabilities: APLT's short term assets ($135.3M) exceed its long term liabilities ($1.1M).


Debt to Equity History and Analysis

Debt Level: APLT's debt to equity ratio (2.8%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if APLT's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: APLT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: APLT has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 62.1% each year.


Dividend

What is Applied Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate APLT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate APLT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if APLT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if APLT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of APLT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Shoshana Shendelman (42 yo)

no data

Tenure

US$4,570,649

Compensation

Dr. Shoshana Shendelman, PhD, has been Director of Applied Therapeutics Inc. since January 2016. Prior to founding Applied, she founded Clearpoint Strategy Group, a boutique strategic advisory firm in NYC,...


CEO Compensation Analysis

Compensation vs Market: Shoshana's total compensation ($USD4.57M) is above average for companies of similar size in the US market ($USD1.70M).

Compensation vs Earnings: Shoshana's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: APLT's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: APLT's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: APLT insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.6%.


Top Shareholders

Company Information

Applied Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Applied Therapeutics, Inc.
  • Ticker: APLT
  • Exchange: NasdaqGM
  • Founded: 2016
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$434.290m
  • Shares outstanding: 26.18m
  • Website: https://www.appliedtherapeutics.com

Number of Employees


Location

  • Applied Therapeutics, Inc.
  • 545 Fifth Avenue
  • Suite 1400
  • New York
  • New York
  • 10017
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/19 23:52
End of Day Share Price2021/10/19 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.